	US 11,814,563 B2
	Bioreachable chiral dopants for liquid crystal applications
Adam Safir, Berkeley, CA (US); Shilpa Naresh Raja, Emeryville, CA (US); Arjan Zoombelt, Emeryville, CA (US); Robert J. Twieg, Kent, OH (US); Pawan Nepal, Kent, OH (US); Ashani Wedige-Fernando, Kent, OH (US); and Peter Palffy-Muhoray, Kent, OH (US)
Assigned to Zymergen Inc., Emeryville, CA (US); and Kent State University, Kent, OH (US)
Appl. No. 17/299,777
Filed by Zymergen Inc., Emeryville, CA (US); and Kent State University, Kent, OH (US)
PCT Filed Dec. 6, 2019, PCT No. PCT/US2019/065055 § 371(c)(1), (2) Date Jun. 3, 2021, PCT Pub. No. WO2020/159620, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/776,957, filed on Dec. 7, 2018.
Prior Publication US 2022/0025267 A1, Jan. 27, 2022
Int. Cl. C09K 19/58 (2006.01)

CPC C09K 19/588 (2013.01)

6 Claims

1. A liquid-crystalline material comprising at least one chiral dopant selected from the group consisting of the structures

wherein R₁, R₂, R₃, and R₄are each independently hydrogen, an aliphatic moiety, an aryl moiety, an arylalkylene moiety, an alkyl arylene moiety, an alkanoyl moiety, an arylalkanoyl moiety, or any halogenated derivative of the foregoing moieties, and

wherein Z is selected from C(H)R₅, —CR₅═CR₅—, O, S, or NRs, wherein R₅is independently hydrogen, an aliphatic moiety, an aryl moiety, an arylalkylene moiety, an alkyl arylene moiety, an alkanoyl moiety, an arylalkanoyl moiety, or any halogenated derivative of the foregoing moieties, and

a nematic or a nematogenic substance.